Loading...
•
Sep 30, 2021
Madrigal Q3 2021 Earnings Report
Madrigal's financial position remained strong, and the company continued to advance its Phase 3 clinical program for resmetirom.
Key Takeaways
Madrigal Pharmaceuticals reported its third quarter 2021 financial results and provided a corporate update, highlighting the progress of its MAESTRO-NASH and MAESTRO-NAFLD-1 studies and the presentation of data at The Liver Meeting® 2021.
Madrigal is on track to complete the double-blind portion of the Phase 3 MAESTRO-NAFLD-1 study and report topline data by year-end.
Additional data from the open-label portion of the MAESTRO-NAFLD-1 study will be presented at AASLD's The Liver Meeting®.
Madrigal announced an alliance with the Fatty Liver Foundation to support the NAFLD Screening Fund.
Stephen Dodge and Kia Motesharei have joined Madrigal as Senior Vice President and Global Head of Medical Affairs and Senior Vice President Business & Corporate Development, respectively.
Madrigal
Madrigal
Forward Guidance
Madrigal anticipates topline data from the double-blind portion of its Phase 3 MAESTRO-NAFLD-1 study by year-end 2021, with additional data rollout in early 2022.
Positive Outlook
- On track to complete the double-blind portion of MAESTRO-NAFLD-1.
- Topline data from MAESTRO-NAFLD-1 expected by year-end.
- Additional data rollout from MAESTRO-NAFLD-1 in early 2022.
- Advancing MAESTRO-NASH, the pivotal serial liver biopsy study.
- Presenting additional data from the open-label portion of MAESTRO-NAFLD-1 at AASLD.
Challenges Ahead
- Clinical development of resmetirom is subject to risks and uncertainties.
- Enrollment uncertainties may arise, particularly in relation to COVID-19-related measures.
- Outcomes or trends from competitive studies could impact results.
- Future topline data timing or results are uncertain.
- Achieving potential benefits in studies with substantially more patients than prior studies carries risks.